8 / 31
Development of Prosigna is Based on PAM50 Gene Signature
2000
Researchers first describe
breast cancer intrinsic subtypes
based on microarray
experiments
2009
Researchers first describe
“PAM50” gene expression
signature
2010
NanoString exclusively
licenses PAM50 gene
expression signature
2013
Prosigna launches
after receiving FDA
510k clearance in US
and CE Mark for
Europe and Israel
PAM50 developed by a consortium of four academic breast cancer
experts
●
Charles Perou, PhD, University of North Carolina
●
Dr. Matt Ellis, Washington University School of Medicine
●
Torsten Nielsen, MD, PhD, Pathologist, BC Cancer Agency
●
Philip Bernard, MD, University of Utah / Huntsman Cancer
Institute
Source:
Molecular portraits of breast cancer.
Nature. 2000 May 25;.
Source:
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, JCO.2009